Cassava Sciences Inc SAVA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Cassava Sciences Shares Lower Premarket on $40 Million Penalty to Settle Doctored Data Claims
-
SEC Charges Cassava Sciences, Former Executives for Misleading Claims in Alzheimer's Trial
-
Cassava Sciences settles SEC charges of 'misleading' Alzheimer's trial claims
-
Cassava Sciences Resolves SEC Investigation
-
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
-
Cassava Sciences Names Rick Barry as Chief Executive Officer
-
Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference
-
Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates
Trading Information
- Previous Close Price
- $31.87
- Day Range
- $26.10–30.33
- 52-Week Range
- $8.79–42.20
- Bid/Ask
- $28.35 / $28.49
- Market Cap
- $1.37 Bil
- Volume/Avg
- 5.8 Mil / 3.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer’s disease dementia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 29
- Website
- https://www.cassavasciences.com
Comparables
Valuation
|
Metric
|
SAVA
|
AVXL
|
UTHR
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 18.27 |
Price/Book Value | 7.23 | 3.71 | 2.80 |
Price/Sales | — | — | 6.74 |
Price/Cash Flow | — | — | 14.46 |
Price/Earnings
SAVA
AVXL
UTHR
Financial Strength
|
Metric
|
SAVA
|
AVXL
|
UTHR
|
|---|---|---|---|
Quick Ratio | 3.93 | 11.95 | 3.92 |
Current Ratio | 4.07 | 12.04 | 4.35 |
Interest Coverage | — | — | 22.67 |
Quick Ratio
SAVA
AVXL
UTHR
Profitability
|
Metric
|
SAVA
|
AVXL
|
UTHR
|
|---|---|---|---|
Return on Assets (Normalized) | −3.99% | −22.21% | 16.95% |
Return on Equity (Normalized) | −4.97% | −24.06% | 20.53% |
Return on Invested Capital (Normalized) | −10.16% | −28.37% | 16.62% |
Return on Assets
SAVA
AVXL
UTHR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Tbzbprlpf | Slxzv | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Wzmqnmr | Ssmjpp | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Zszynfh | Ddythk | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Mslngkys | Kdwqgr | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Hxrmtqrwn | Lkn | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Kzfwyxgq | Flmr | $28.1 Bil | |||
| Moderna Inc
MRNA
| Hfzgyswcl | Ygm | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Rxdgbzp | Rqf | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Grqmrhmfs | Wfwgc | $13.4 Bil | |||
| Incyte Corp
INCY
| Wsqnncws | Sgrskr | $12.7 Bil |
United States